Viridian reports positive VRDN-008 Phase 1 results with every-8-week dosing
FROM THE WIRE · FINANCE.YAHOO.COM
- VRDN-008, a half-life extended FcRn inhibitor, demonstrated deep and sustained IgG reduction through 8 weeks after subcutaneous dosing in healthy volunteers, with 74% reduction at peak - - VRDN-008 demonstrated an extended half-life of 15–18 days, up to 6x longer than the…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishPositive Phase 1 data support the potential profile of VRDN-008 and plans for pivotal trials in 2027.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01VRDN-008 showed a 74% IgG reduction at peak and sustained reduction through 8 weeks in healthy volunteers.
- 02Half-life of 15-18 days, up to 6x longer than first-generation Fc fragments.
- 03Viridian plans at least one pivotal trial in 2027, starting with myasthenia gravis in mid-2027, pending regulatory feedback.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets